[1] International Monetary Fund. A Crisis Like No Other, An Uncertain Recovery[EB/OL]. (2020-06-24)[2020-09-21].https://www.imf.org/en/Publications/WEO/Issues/2020/06/24/WEOUpdateJune2020. [2] WHO. WHO Coronavirus Disease (COVID-19) Dashboard[EB/OL]. (2020-09-20)[2020-09-21].https://covid19.who.int. [3] WHO. Draft landscape of COVID-19 candidate vaccines2020[EB/OL].(2020-09-28)[2020-09-30].https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. [4] London School of Hygiene & Tropical Medicine. Current COVID-19 vaccine candidates2020[EB/OL].(2020-09-29)[2020-09-30]. https://www.lshtm.ac.uk/research/centres/vaccine-centre/covid-19. [5] Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine[J/OL]. Am J Epidemiol,1969,89:422-434[2020-09-30].https://doi.org/10.1093/oxfordjournals.aje.a120955. [6] Smatti MK, Al Thani AA, Yassine HM.Viral-Induced Enhanced Disease Illness[J/OL].Front Microbiol,2018,9:5[2020-09-21]. https://doi.org/10.3389/fmicb.2018.02991. [7] Lambert PH, Ambrosino DM, Andersen SR, et al.Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines[J/OL]. Vaccine, 2020,38:4783-4791[2020-09-21]. https://doi.org/10.1016/j.vaccine.2020.05.064. [8] Global Pharmacovigilance. Glossary of Drug Safety Terms2020 [EB/OL].[2020-09-30]. https://globalpharmacovigilance.tghn.org/resources/glossary/#link_seven. [9] Barbara Law, Sturkenboom. Priority List of Adverse Events of Special Interest: COVID-19. Bright Collab2020:1-52[EB/OL]. (2020-06-10)[2020-09-30]. https://brightoncollaboration.us/category/news/covid/. [10] Global Advisory Committee on Vaccine Safety (GACVS). Addressed pharmacovigilance preparedness for the launch of the future COVID-19 vaccines[J]. Wkly Epidemiol Rec,2020,95:325-336. [11] Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19[J/OL]. N Engl J Med, 2020,383:1085-1087[2020-09-21]. https://doi.org/10.1056/NEJMc2025179. [12] Li Ki, Zhang L, Ye JK, et al.Surveillance of adverse events following immunization in China, 2017[J]. Chinese Journal of vaccines and immunization(中国疫苗和免疫), 2020,26(1):9-18. [13] Wu WD, Liu DW, Li KL,et al.Using proportional reporting ratio to detect vaccine reaction signals of post-marketing varicel-la live attenuated vaccine in china[J]. Chinese journal of vaccines and immunization(中国疫苗和免疫), 2015, 21(5):552-556. [14] Tavares-Da-Silva F, Co MM, Dessart C, et al. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine[J/OL]. Vaccine 2020,38:3489-3500[2020-09-21]. https://doi.org/10.1016/j.vaccine.2019.11.058. [15] Zeng J,Tang T, Wang YJ, et al.Post-marketing multi-center safety surveillance of inactivated enterovirus A71 vaccine (Vero cell)[J/OL]. Chin J Prev Med(中华预防医学杂志), 2019, 53(03):252-257[2020-09-21]. https://doi.org/10.3760/cma.j.issn.0253-9624.2019.03.003. [16] Shen LZ, Fu J, Pan XJ.Post-marketing observation on safety of inactivated enterovirus A71 vaccine (human diploid cell)[J/OL]. Chin J Prev Med(中华预防医学杂志), 2019, 53(03): 258-261[2020-09-21]. https://doi.org/10.3760/cma.j.issn.0253-9624.2019.03.004. [17] Xu YY, Xu EP, Li Q, et al.Active surveillance for domestically produced inactivated Japanese encephalitis vaccine[J/OL]. Zhejiang Prev Med(浙江预防医学), 2016, 28:600-603[2020-09-21]. https://doi.org/10.19485/j.cnki.issn1007-0931.2016.06.016. [18] Li Keli, Liu Dawei, Wu Wendi, et al.Study on the Incidence of Hospitalized Thrombocytopenic Purpura Cases in 6 Cities in China, 2007-2009[J]. Chinese Journal of vaccines and immunization(中国疫苗和免疫),2012,18:139-143. [19] Wu J, Xu F, Lu L, et al. Safety and Effectiveness of a2009 H1N1 Vaccine in Beijing[J/OL]. N Engl J Med,2010,363:2416-2423 [2020-09-21]. https://doi.org/10.1056/NEJMoa1006736. [20] Zhu F, Guan X, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial[J/OL]. Lancet, 2020,396: 479-488[2020-09-21]. https://doi.org/10.1016/S0140-6736(20)31605-6. [21] WHO. Causality assessment of an adverse event following immunization (updated user manual for the revised WHO classi-fication second edition)[M/OL].2019:1-48[2020-09-21]. https://www.who.int/vaccine_safety/publications/gvs_aefi/en/. [22] Cai T, Liu LL, Yao XY, et al. Scoping review of active surveillance systems for vaccine safety world-wide[J/OL]. Chin J Prev Med(中华预防医学杂志), 2019, 53(07): 724-730[2020-09-21]. https://doi.org/10.3760/cma.j.issn.0253-9624. [23] Yu MK, Xie Z, Yan XR,et al.Empirical analysis on improving influenza vaccination rate in Beijing[J/OL]. Chin J Appl Clin Pediatr(中华实用儿科临床杂志), 2019, 34(02):116-119[2020-09-21]. https://doi.org/10.3760/cma.j.issn.2095-428X.2019.02.008. [24] Ball P, Maxmen A. The epic battle against coronavirus misinfor-mation and conspiracy theories[J/OL]. Nature,2020,581:371-374[2020-09-21]. https://doi.org/10.1038/d41586-020-01452-z. [25] Li J, Zhang ZJZ, Lu L, et al.The role of new traditional media and social media in public opinion dissemination about the Shandong Illegal Vaccine Selling Event[J]. Chinese Journal of vaccines and immunization(中国疫苗和免疫), 2018,24:221-225. [26] Brighton Collaboration. Standardized Template for Collection of Key Information for Benefit-Risk Assessment of Vaccines[EB/OL]. (2020-06-11)[2020-09-30]. https://brightoncollaboration. us/category/news/covid/. [27] Chen RT, Carbery B, Mac L, et al.The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)[J/OL]. Vaccine, 2015,33:73-75[2020-09-21]. https://doi.org/10.1016/j.vaccine.2014.09.035. [28] Vaccine monitoring collaboration for Europe. COVID-19 vaccine monitoring [EB/OL].[2020-09-30] https://vac4eu.org/covid-19-vaccine-monitoring/. [29] World Health Organization. The Global Advisory Committee on Vaccine Safety2020[EB/OL].[2020-09-30]https://www.who.int/vaccine_safety/committee/en/. |